McClellan: post-market data best for gauging new technology in US
This article was originally published in Clinica
Executive Summary
Medicare's top administrator, Mark McClellan, is promising to play a greater role in encouraging post-market studies, believing these are less costly and more useful than the data available from the hot-house world of the clinical trial.
You may also be interested in...
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.